Biogen, Eli Lilly drugs to expand imaging market for companies in diagnostics sector.
Tag: neurodegenerative disease drugs
Biogen to Cut Roughly 11% of Workforce to Focus on Big-Return Drugs
The biotech company cited the launch of Alzheimer’s drug Lekembi as part of its new focus…
FDA Approves Leqembi, Extending Alzheimer’s Treatment to More Patients
The agency’s full approval may result in people enrolled in Medicare receiving anti-amyloid treatment.
Alzheimer’s Blockbuster Is Coming, but Slowly
The developers of Alzheimer’s drugs have worked hard to make treatment available to patients.
Alzheimer’s Blockbuster Is Coming, but Slowly
The developers of Alzheimer’s drugs have worked hard to make treatment available to patients.
Medicare Plans to Cover Alzheimer’s Drugs
Biogen and Eisai’s Leqembi is slated for full approval this summer.
Biogen Boss Turns Corner on Alzheimer’s Miscues
The biotech company needs to embark on a new growth path as former Sanofi CEO Chris…
Collecting Pharma’s Scraps Can Pay Off for This Biotech
Market heard on the street Roivant has created a unique model that allows it to take…
Opinion | Denying Alzheimer’s Treatments
Eli Lilly’s drug shows great results, but will the federal government block access?